-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Receives $32.90 Average Target Price From Brokerages
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Receives $32.90 Average Target Price From Brokerages
Nurix Therapeutics, Inc. (NASDAQ:NRIX – Get Rating) has been given a consensus rating of "Moderate Buy" by the ten research firms that are currently covering the company, MarketBeat reports. One analyst has rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $32.90.
A number of research firms have recently weighed in on NRIX. HC Wainwright dropped their target price on shares of Nurix Therapeutics to $53.00 in a report on Thursday, October 13th. Morgan Stanley assumed coverage on Nurix Therapeutics in a research note on Tuesday, October 11th. They set an "equal weight" rating and a $11.00 target price on the stock. Finally, SVB Leerink cut their price target on shares of Nurix Therapeutics from $37.00 to $28.00 and set an "outperform" rating on the stock in a report on Tuesday, December 13th.
Get Nurix Therapeutics alerts:Nurix Therapeutics Stock Up 7.3 %
Shares of NASDAQ NRIX opened at $13.26 on Friday. The firm's fifty day moving average is $11.69 and its 200 day moving average is $13.45. Nurix Therapeutics has a 52 week low of $7.52 and a 52 week high of $20.20. The company has a market cap of $625.21 million, a price-to-earnings ratio of -3.57 and a beta of 1.65.
Institutional Trading of Nurix Therapeutics
Hedge funds and other institutional investors have recently modified their holdings of the business. BlackRock Inc. boosted its stake in Nurix Therapeutics by 11.0% during the third quarter. BlackRock Inc. now owns 3,723,090 shares of the company's stock worth $48,512,000 after acquiring an additional 367,743 shares in the last quarter. State Street Corp boosted its position in shares of Nurix Therapeutics by 9.2% in the 3rd quarter. State Street Corp now owns 2,312,224 shares of the company's stock worth $30,128,000 after purchasing an additional 195,453 shares in the last quarter. Vanguard Group Inc. grew its stake in shares of Nurix Therapeutics by 2.3% in the 3rd quarter. Vanguard Group Inc. now owns 2,160,866 shares of the company's stock worth $28,156,000 after buying an additional 49,370 shares during the last quarter. ARK Investment Management LLC increased its position in Nurix Therapeutics by 54.5% during the 4th quarter. ARK Investment Management LLC now owns 1,988,254 shares of the company's stock valued at $21,831,000 after buying an additional 701,732 shares in the last quarter. Finally, Bain Capital Life Sciences Investors LLC increased its position in Nurix Therapeutics by 41.9% during the 2nd quarter. Bain Capital Life Sciences Investors LLC now owns 1,822,883 shares of the company's stock valued at $23,096,000 after buying an additional 538,570 shares in the last quarter. 91.33% of the stock is owned by hedge funds and other institutional investors.About Nurix Therapeutics
(Get Rating)
Nurix Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.
See Also
- Get a free copy of the StockNews.com research report on Nurix Therapeutics (NRIX)
- Cathie Woods' Ark Innovation ETF Set To Rebound in 2023?
- Mullen Automotive Stock Gains Momentum On Positive News
- Harley-Davidson Inc. Stock, Is It Time To Buy?
- The Bottom Is In For Meta Platforms, Volatility Is Not Over
- Analyzing Alaska Air's Recent Earnings
Receive News & Ratings for Nurix Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nurix Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
据MarketBeat报道,Nurix治疗公司(纳斯达克代码:NRIX-GET评级)已被目前报道该公司的十家研究公司一致给予“中等买入”的评级。一名分析师对该股的评级为持有建议,六名分析师给出了买入建议。在去年更新了对该股覆盖范围的券商中,12个月目标价的平均水平为32.90美元。
最近,许多研究公司都加入了NRIX的行列。在10月13日星期四的一份报告中,HC Wainwright将Nurix治疗公司的股票目标价下调至53.00美元。摩根士丹利在10月11日星期二的一份研究报告中承担了对Nurix Treateutics的报道。他们为该股设定了“同等权重”的评级和11.00美元的目标价。最后,SVB Leerink在12月13日(星期二)的一份报告中将Nurix Treateutics的股票目标价从37.00美元下调至28.00美元,并对该股设定了“跑赢大盘”的评级。
到达纽瑞克斯治疗公司警报:Nurix Treateutics股票上涨7.3%
上周五,纳斯达克NRIX的股价开盘报13.26美元。该公司的50日移动均线切入位为11.69美元,200日移动均线切入位为13.45美元。Nurix Treateutics的52周低点为7.52美元,52周高位为20.20美元。该公司市值为6.2521亿美元,市盈率为-3.57倍,贝塔系数为1.65。
纽瑞克斯治疗公司的制度性交易
对冲基金和其他机构投资者最近调整了对该公司的持股。贝莱德股份有限公司在第三季度增持了纽瑞克斯治疗公司11.0%的股份。贝莱德股份有限公司在上个季度增持了367,743股后,目前持有该公司3,723,090股股票,价值48,512,000美元。道富集团在第三季度将其在Nurix Treateutics的股票头寸增加了9.2%。道富银行目前持有该公司2,312,224股股票,价值30,128,000美元,上一季度又购买了195,453股。先锋集团(Vanguard Group Inc.)在第三季度增持了Nurix治疗公司的股份2.3%。先锋集团目前持有2,160,866股该公司股票,价值28,156,000美元,上一季度又购买了49,370股。方舟投资管理公司在第四季度将其在Nurix治疗公司的头寸增加了54.5%。方舟投资管理有限责任公司现在拥有1,988,254股该公司股票,价值21,831,000美元,上个季度又购买了701,732股。最后,贝恩资本生命科学投资者有限责任公司在第二季度将其在Nurix治疗公司的头寸增加了41.9%。贝恩资本生命科学投资者有限责任公司现在拥有1,822,883股该公司股票,价值23,096,000美元,上个季度又购买了538,570股。91.33%的股票由对冲基金和其他机构投资者持有。关于Nurix Treateutics
(获取评级)
Nurix治疗公司是一家生物制药公司,专注于治疗癌症和免疫疾病的小分子疗法的发现、开发和商业化。该公司开发了用于治疗复发或难治性B细胞恶性肿瘤的口服布鲁顿酪氨酸激酶(BTK)降解剂NX-2127;用于治疗复发或难治性B细胞恶性肿瘤和自身免疫性疾病的口服生物可用BTK降解剂NX-5948;以及口服可用于免疫肿瘤学适应症的Casitas B细胞性淋巴瘤原癌基因B(CBL-B)抑制剂NX-1607。
另请参阅
- 免费获取StockNews.com关于Nurix治疗的研究报告(NRIX)
- 凯西·伍兹的方舟创新ETF将在2023年反弹?
- 马伦汽车公司股票因利好消息而上涨
- 哈雷-戴维森公司的股票,是时候买入了吗?
- Meta平台的底部已经到了,波动性还没有结束
- 阿拉斯加航空公司近期收益分析
接受《Nurix治疗日报》的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Nurix Treateutics和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧